MannucciPM, RuggeriZM, ParetiFI, CapitanioA: 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet, 1977; 1:869–872.
2.
LeissingerC, BectonD, CornellCJr., Cox GillJ: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia, 2001; 7:258–266.
3.
LuoGP, NiB, YangX, WuYZ: von Willebrand factor: more than a regulator of hemostasis and thrombosis. Acta Haematol, 2012; 128:158–169.
4.
GaronaJ, PifanoM, ScursoniAM, GomezDE, AlonsoDF, RipollGV: Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice. Anticancer Res, 2014; 34:4761–4765.
5.
PifanoM, GaronaJ, CapobiancoCS, GonzalezN, AlonsoDF, RipollGV: Peptide agonists of vasopressin V2 receptor reduce expression of neuroendocrine markers and tumor growth in human lung and prostate tumor cells. Front Oncol, 2017; 7:11.
6.
SasakiH, KlotzLH, SugarLM, KissA, VenkateswaranV: A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells. Biochem Biophys Res Commun, 2015; 464:848–854.
7.
ZhangCL, McKinseyTA, ChangS, AntosCL, HillJA, OlsonEN: Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell, 2002; 110:479–488.
dos SantosDO, BlefariV, PradoFP, et al.: Reduced expression of adherens and gap junction proteins can have a fundamental role in the development of heart failure following cardiac hypertrophy in rats. Exp Mol Pathol, 2016; 100:167–176.
10.
FontesMS, RaaijmakersAJ, van DoornT, et al.: Changes in Cx43 and NaV1.5 expression precede the occurrence of substantial fibrosis in calcineurin-induced murine cardiac hypertrophy. PLoS One, 2014; 9:e87226.
11.
WillisMS, HolleyDW, WangZ, et al.: BRG1 and BRM function antagonistically with c-MYC in adult cardiomyocytes to regulate conduction and contractility. J Mol Cell Cardiol, 2017; 105:99–109.
12.
HsuMC, ChangCS, LeeKT, et al.: Central obesity in males affected by a dyslipidemia-associated genetic polymorphism on APOA1/C3/A4/A5 gene cluster. Nutr Diabetes, 2013; 3:e61.
13.
HsiaoTJ, HwangY, ChangHM, LinE: Association of the rs6235 variant in the proprotein convertase subtilisin/kexin type 1 (PCSK1) gene with obesity and related traits in a Taiwanese population. Gene, 2014; 533:32–37.
14.
YueH, HeJW, KeYH, et al.: Association of single nucleotide polymorphism Rs2236518 in PRDM16 gene with BMI in Chinese males. Acta Pharmacol Sin, 2013; 34:710–716.
15.
TimblinB, RehliM, SkidgelRA: Structural characterization of the human carboxypeptidase D gene and its promoter. Int Immunopharmacol, 2002; 2:1907–1917.
16.
NedogodaSV, LedyaevaAA, ChumachokEV, et al.: Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig, 2013; 33:553–561.
17.
PuJ, GuardiaCM, Keren-KaplanT, BonifacinoJS: Mechanisms and functions of lysosome positioning. J Cell Sci, 2016; 129:4329–4339.
18.
JensenSS, PettersonSA, HalleB, Aaberg-JessenC, KristensenBW: Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo. BMC Cancer, 2017; 17:178.
AqbaniEO, van den BoschMT, BrownE, et al.: Coordinated membrane ballooning and procoagulant spreading in human platelets. Circulation, 2015; 132:1414–1424.
21.
SiffertW, FoxG, GrosG: The effect of carbonic anhydrase inhibition on the velocity of thrombin-stimulated platelet aggregation under physiological conditions. Biochem Biophys Res Commun, 1984; 121:266–270.
22.
VaitkeviciusH, TurnerI, SpaldingA, LocketteW: Chloride increases adrenergic receptor-mediated platelet and vascular responses. Am J Hypertens, 2002; 15:492–498.
23.
GendeOA: Thrombin stimulation of Cl-/HCO3-exchange in human platelets. Thromb Res, 2005; 116:67–73.
24.
Vega LdeL, MuñozE, CalzadoMA, et al.: The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway. Biochem Pharmacol, 2005; 70:369–380.
UemaetomariI, TabuchiK, HoshinoT, HaraA: Protective effect of calcineurin inhibitors on acoustic injury of the cochlea. Hear Res, 2005; 209:86–90.
27.
TaslimiS, VahidiH, PourvaziriA, et al.: Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study. Eur Arch Otorhinolaryngol, 2013; 270:1635–1641.
28.
LangfordRM, KnaggsR, Farquhar-SmithP, DickensonAH: Is tapentadol different from classical opioids? A review of the evidence. Br J Pain, 2016; 10:217–221.
29.
HednerT, SamulessonO, WährborgP, WadenvikH, UngKA, EkbomA: Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs, 2004; 64:2315–2343.
30.
MartinJC, HitchcockMJ, De ClercqE, PrusoffWH: Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides. Antiviral Res, 2010; 85:34–38.
31.
PanJ, CaiH: Opioid system in L-DOPA-induced dyskinesia. Transl Neurodegener, 2017; 6:1.
32.
TeemaAM, ZaitoneSA, MoustafaYM: Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: influence on angiogenesis. Neuropharmacology, 2016; 107:432–450.
33.
OztekinNS, SaygiSS, DalkaraT, SensesI, ZileliT: High dose anticholinergic therapy (biperiden) in dystonia. Clin Neurol Neurosurg, 1991; 93:35–37.
34.
SudoY, SuharaT, SuzukiK, et al.: Muscarinic receptor occupancy by biperiden in living human brain. Life Sci, 1999; 64:PL99–PL104.
35.
EltzeM, FigalaV: Affinity and selectivity of biperiden enantiomers for muscarinic receptor subtypes. Eur J Pharmacol, 1988; 158:11–19.
36.
JackischR, KruchenA, SauermannW, HerttingG, FeuersteinTJ: The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists. Eur J Pharmacol, 1994; 264:207–211.
37.
KornhuberJ, MuehlbacherM, TrappS, et al.: Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One, 2011; 6:e23852.
38.
NagelD, SprangerS, VincendeauM, et al.: Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell, 2012; 22:825–837.
39.
SpindelER: Muscarinic receptor agonists and antagonists: effects on cancer. Handb Exp Pharmacol, 2012;(208):451–468.
40.
AckermanMS, RoeskeWR, HeckRJ, KorcM: Identification and characterization of muscarinic receptors in cultured human pancreatic carcinoma cells. Pancreas, 1989; 4:363–370.
41.
SugayaK, KadekawaK, IkeharaA, et al.: Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol, 2003; 10:569–574.
42.
HerbigU, SedivyJM: Regulation of growth arrest in senescence: telomere damage is not the end of the story. Mech Ageing Dev, 2006; 127:16–24.
43.
DejanaE, OrsenigoF, LampugnaniMG: The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci, 2008; 121(Pt 13):2115–2122.
44.
PasanisiF, ImperatoreG, VaccaroO, IovineC, FerraraLA: Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension. Nutr Metab Cardiovasc Dis, 1999; 9:73–77.
45.
KirkJK, KonenJC, ShihabiZ, RoccoMV, SummersonJH: Effects of terazosin on glycemic control, cholesterol, and microalbuminuria in patients with non-insulin-dependent diabetes mellitus and hypertension. Am J Ther, 1996; 3:616–621.
46.
Al-SaediZ, ZimmermanA, BachuRD, et al.: Dry eye disease: present challenges in the management and future trends. Curr Pharm Des, 2016; 22:4470–4490.
47.
EsmaeliB, DibaR, AhmadiMA, et al.: Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye (Lond), 2004; 18:760–762.
48.
HuangJF, YafawiR, ZhangM, et al.: Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology, 2012; 119:e43–e50.
WalshCJ, BattJ, HerridgeMS, et al.: Transcriptomic analysis reveals abnormal muscle repair and remodeling in survivors of critical illness with sustained weakness. Sci Rep, 2016; 6:29334.
51.
BougléA, RocheteauP, SharsharT, ChrétienF: Muscle regeneration after sepsis. Crit Care, 2016; 20:131.
52.
NardelliP, KhanJ, PowersR, CopeTC, RichMM: Reduced motoneuron excitability in a rat model of sepsis. J Neurophysiol, 2013; 109:1775–1781.
53.
JacksonDA, WhiteSR: Receptor subtypes mediating facilitation by serotonin of excitability of spinal motoneurons. Neuropharmacology, 1990; 29:787–797.
